Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.
about
Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group.Colistin vs. Ceftazidime-avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae.Novel Method Suggests Global Superiority of Short-Duration Antibiotics for Intra-abdominal Infections.Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations
P2860
Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Using Outcomes to Analyze Pati ...... sm in Benefit:risk Evaluation.
@en
type
label
Using Outcomes to Analyze Pati ...... sm in Benefit:risk Evaluation.
@en
prefLabel
Using Outcomes to Analyze Pati ...... sm in Benefit:risk Evaluation.
@en
P2860
P1476
Using Outcomes to Analyze Pati ...... sm in Benefit:risk Evaluation.
@en
P2093
Dean Follmann
Scott R Evans
P2860
P304
P356
10.1080/19466315.2016.1207561
P577
2016-12-06T00:00:00Z